Philippe Menu
Known title: Chief Medical OfficerCIK: 0002014308
Associated companies
Transaction History
| SOPH | ▼ Sell | Open Market | 5,000 | $39K | 9/14/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $43K | 8/25/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $38K | 8/12/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $28K | 7/27/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $29K | 7/13/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 7,393 | $38K | 7/6/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $28K | 6/25/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $25K | 6/12/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $25K | 5/26/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 608 | $3K | 5/19/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $23K | 5/12/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 5,000 | $24K | 4/27/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 608 | $3K | 4/20/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 1,600 | $8K | 4/14/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 1,000 | $5K | 4/13/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 3,400 | $16K | 4/13/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 3,725 | $17K | 4/10/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 1,931 | $9K | 4/9/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,800 | $14K | 4/8/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,400 | $12K | 4/7/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 2,700 | $13K | 4/6/2026 | View on chart |
| SOPH | ▲ Buy | Grant | 112,936 | $0 | 4/2/2026 | View on chart |
| SOPH | ▼ Sell | Open Market | 608 | $3K | 3/19/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum
Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.
SOPHiA GENETICS Shares Rise 7% Amid Questions on Momentum. Shares of SOPHiA GENETICS climbed 7% in early trading, pushing the stock toward the upper end of its 52‑week range. The move comes with an RSI of 55.5, indicating moderate momentum, and the stock remains above the $4.85 support level that has been tested 13 times. Analysts keep a target of $9.75, but the recent gain raises questions about how long the upward trend can continue.